Comparison of Xenetic Biosciences Inc. (XBIO) and ImmunoCellular Therapeutics Ltd. (OTCMKTS:IMUC)

As Biotechnology businesses, Xenetic Biosciences Inc. (NASDAQ:XBIO) and ImmunoCellular Therapeutics Ltd. (OTCMKTS:IMUC), are affected by contrast. This especially applies to their risk, analyst recommendations, profitability, institutional ownership, dividends, earnings and valuation.

Valuation and Earnings

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Xenetic Biosciences Inc. N/A 0.00 10.68M -0.81 0.00
ImmunoCellular Therapeutics Ltd. N/A 0.00 9.03M -0.48 0.00

Table 1 demonstrates Xenetic Biosciences Inc. and ImmunoCellular Therapeutics Ltd.’s gross revenue, earnings per share (EPS) and valuation.


Table 2 hightlights the net margins, return on equity and return on assets of the two companies.

Net Margins Return on Equity Return on Assets
Xenetic Biosciences Inc. 0.00% -62.3% -45.1%
ImmunoCellular Therapeutics Ltd. 0.00% -321.9% -158.6%

Risk & Volatility

Xenetic Biosciences Inc.’s current beta is 2.1 and it happens to be 110.00% more volatile than Standard & Poor’s 500. Competitively, ImmunoCellular Therapeutics Ltd.’s 131.00% volatility makes it less volatile than Standard & Poor’s 500, because of the -0.31 beta.


Xenetic Biosciences Inc.’s Current Ratio is 0.7 while its Quick Ratio is 0.7. On the competitive side is, ImmunoCellular Therapeutics Ltd. which has a 9.5 Current Ratio and a 9.5 Quick Ratio. ImmunoCellular Therapeutics Ltd. is better positioned to pay off short and long-term obligations compared to Xenetic Biosciences Inc.

Institutional & Insider Ownership

Roughly 11% of Xenetic Biosciences Inc. shares are owned by institutional investors while 4.3% of ImmunoCellular Therapeutics Ltd. are owned by institutional investors. 58.2% are Xenetic Biosciences Inc.’s share owned by insiders. Competitively, ImmunoCellular Therapeutics Ltd. has 0.3% of it’s share owned by insiders.


In this table we show the Weekly, Monthly, Quarterly, Half Yearly, Yearly and YTD Performance of both pretenders.

Performance (W) Performance (M) Performance (Q) Performance (HY) Performance (Y) Performance (YTD)
Xenetic Biosciences Inc. -10.37% -23.4% -40.46% -54.18% -34.6% -26.22%
ImmunoCellular Therapeutics Ltd. -18.15% -21.62% -21.77% -36.31% -92.54% 19.88%

For the past year Xenetic Biosciences Inc. had bearish trend while ImmunoCellular Therapeutics Ltd. had bullish trend.


On 4 of the 6 factors ImmunoCellular Therapeutics Ltd. beats Xenetic Biosciences Inc.

Xenetic Biosciences, Inc., a clinical stage biopharmaceutical company, focuses on the discovery, research, and development of biologic drugs and orphan oncology therapeutics. Its lead proprietary technology is PolyXen, a platform technology for biologic drug delivery. The companyÂ’s lead drug candidate is XBIO-101, a small-molecule immunomodulator and interferon inducer for the treatment of progesterone receptor negative endometrial cancer and triple negative breast cancer. It also develops OncoHist for the treatment of acute myeloid leukemia. The company has a research, development, license, and supply agreement with Shire plc to develop SHP656, a polysialylated recombinant (rFVIII) protein to treat hemophilia; and a collaborative research and development license agreement with PJSC Pharmsynthez to develop, commercialize and market PulmoXen for the treatment of cystic fibrosis, as well as Xemys for the treatment of multiple sclerosis. Xenetic Biosciences, Inc. is headquartered in Lexington, Massachusetts.

ImmunoCellular Therapeutics, Ltd., a clinical-stage biotechnology company, develops immune-based therapies for the treatment of various cancers. Its lead product candidate is ICT-107, a dendritic cell (DC) immunotherapy targeting cancer stem cells (CSCs) and cancer antigens, which is in Phase III clinical trials for the treatment of glioblastoma multiforme (GBM). The company is also developing ICT-140, a DC-based immunotherapy targeting CSCs and cancer antigens that is in Phase I clinical trials for the treatment of ovarian cancer; and ICT-121, a DC-based immunotherapy targeting CD133 markers and CSCs, which is in Phase I clinical trials to treat recurrent GBM and other solid tumor cancers. In addition, it has a portfolio of other potential therapeutic immunotherapies to treat cancer. The company was formerly known as Optical Molecular Imaging, Inc. and changed its name to ImmunoCellular Therapeutics, Ltd. in November 2006. ImmunoCellular Therapeutics, Ltd. is based in Calabasas, California.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.